As EliLilly’s Kisunla (donanemab) enters the Alzheimer’s treatment space, its leading competitor Biogen is undergoing therapy diversification after completing its $1.15bn acquisition of Human Immunology Biosciences (HI-Bio).
Biogen’s head of development Priya Singhal said the company is “very excited” about the addition of felzartamab to its rosters in a 2 July press release, adding that Biogen will advance the candidate to Phase III now the transaction is complete.
Biogen is known for its neuroscience focus, having co-developed the next-generation Alzheimer’s treatment Leqembi (lecanemab-irmb) with Eisai. The drug is predicted to see US sales of $4.6bn by 2030, according to GlobalData’s Pharma Intelligence Centre.
In a previous earnings call, Biogen’s CEO Chris Viehbacher stated the importance of diversifying therapeutic scopes, adding that neuroscience is a “high-risk area.” EliLilly has now consolidated that – at least in the Alzheimer’s space – having secured US Food and Drug Administration (FDA) approval yesterday [2 July] for Leqembi rival Kisunla.
Biogen’s acquisition of HI-Bio’s “pipeline-in-a-product” will expand the former company’s immunology presence. As per a press release announcing the agreement in May, Biogen will keep employees from HI-Bio and establish a team in the San Francisco Bay Area. At the time, Singhal stated that felzartamab is a “strategic addition to the Biogen portfolio” and “will augment [its] pipeline and build on [its] expertise in immunology”.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.